Sheila K. Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sheila K. Patel has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
- Louise M. Burrell
Department of Medicine, The University of Melbourne, Austin Health, Victoria, Australia
29 shared publications - Piyush Mohan Srivastava
Department of Medicine, Melbourne Medical School, University of Melbourne, Melbourne
14 shared publications - Elena Velkoska
Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
7 shared publications - Nigel Unwin
European Centre for Environment and Human Health, University of Exeter, Penryn, United Kingdom
6 shared publications Elena Velkoska
Department of Medicine, Austin Health, University of Melbourne Heidelberg, VIC, Australia
5 shared publications- Amy Brodtmann
Monash University Melbourne Victoria Australia
4 shared publications
Latest Publications
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Associations of Angiotensin‐Converting Enzyme 2 Activity With Markers of Endothelial Dysfunction and Oxidative Stress in Young Healthy Adults: The African‐PREDICT Study
Background: Activation of the renin–angiotensin–aldosterone‐system plays a major role in the pathogenesis of cardiovascular disease through, among others, endothelial dysfunction and oxidative stress. Circulating ACE2 (angiotensin‐converting enzyme 2) is emerging as a biomarker of cardiovascular disease risk; however, its role in younger populations is not well‐established. This study aimed to investigate sex differences in serum ACE2 activity and associations with endothelial dysfunction and oxidative stress‐related markers in young, apparently healthy men and women. Methods: In this cross‐sectional study, we included 1134 young (aged 20–30 years) men (n=557) and women (n=577). Serum ACE2 activity was measured using a validated fluorometric assay. We analyzed markers of endothelial dysfunction, oxidative stress, and antioxidant capacity. We performed a 2‐sample t test and Mann‐Whitney U test. We applied multivariable‐adjusted Tobit regression analysis to account for left truncation. Results: Men had higher ACE2 activity than women ( P P =0.006), and a disintegrin‐like metalloproteinase with thrombospondin motif type 1 member 13 ( P =0.019) in men. Among women, ACE2 activity was negatively associated with asymmetric dimethylarginine ( P =0.043) and superoxide dismutase ( P =0.004). Conclusions: Serum ACE2 activity was higher in men than women and showed sex‐specific associations with endothelial dysfunction and oxidative stress‐related markers. Our results suggest an association between ACE2 shedding and pathophysiological processes associated with alterations in endothelial integrity and early endothelial dysfunction, which may be influenced by sex. This highlights the role of circulating ACE2 as a potential early biomarker of cardiovascular disease risk in young adults. Registration: URL: https://clinicaltrials.gov ; Unique identifier: NCT03292094.
- 20 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (20)
Associations of Angiotensin‐Converting Enzyme 2 Activity With Markers of Endothelial Dysfunction and Oxidative Stress in Young Healthy Adults: The African‐PREDICT Study
Background: Activation of the renin–angiotensin–aldosterone‐system plays a major role in the pathogenesis of cardiovascular disease through, among others, endothelial dysfunction and oxidative stress. Circulating ACE2 (angiotensin‐converting enzyme 2) is emerging as a biomarker of cardiovascular disease risk; however, its role in younger populations is not well‐established. This study aimed to investigate sex differences in serum ACE2 activity and associations with endothelial dysfunction and oxidative stress‐related markers in young, apparently healthy men and women. Methods: In this cross‐sectional study, we included 1134 young (aged 20–30 years) men (n=557) and women (n=577). Serum ACE2 activity was measured using a validated fluorometric assay. We analyzed markers of endothelial dysfunction, oxidative stress, and antioxidant capacity. We performed a 2‐sample t test and Mann‐Whitney U test. We applied multivariable‐adjusted Tobit regression analysis to account for left truncation. Results: Men had higher ACE2 activity than women ( P P =0.006), and a disintegrin‐like metalloproteinase with thrombospondin motif type 1 member 13 ( P =0.019) in men. Among women, ACE2 activity was negatively associated with asymmetric dimethylarginine ( P =0.043) and superoxide dismutase ( P =0.004). Conclusions: Serum ACE2 activity was higher in men than women and showed sex‐specific associations with endothelial dysfunction and oxidative stress‐related markers. Our results suggest an association between ACE2 shedding and pathophysiological processes associated with alterations in endothelial integrity and early endothelial dysfunction, which may be influenced by sex. This highlights the role of circulating ACE2 as a potential early biomarker of cardiovascular disease risk in young adults. Registration: URL: https://clinicaltrials.gov ; Unique identifier: NCT03292094.
- Open Access
- 27 September 2026
- Published by Wiley in Health Expectations
- Vol. 29 (5) , e70884
Beyond Research Priorities: Stakeholder‐Identified Health System Challenges From an Australian Childhood Cancer Priority‐Setting Partnership
Background: Priority‐setting partnerships (PSPs) are used to identify research questions that matter most to patients, caregivers, and clinicians. However, submissions that fall outside the scope of research prioritisation are rarely examined despite their potential to reveal important unmet needs. This study explored concerns relevant to practice and policy using the out‐of‐scope questions submitted during the Australian Child and Adolescent Cancer PSP. Methods: We conducted the Australian Child and Adolescent Cancer PSP with the James Lind Alliance to identify research priorities for childhood cancer. An online national survey collected submissions from children and adolescents diagnosed with cancer, their caregivers, and healthcare professionals. We identified submissions that fell outside the PSP scope. These were collated and analysed using qualitative content analysis, followed by framework analysis to deductively map themes to the World Health Organisation Health System Building Blocks, enabling system‐level interpretation of community‐identified concerns. Results: Of the 701 submissions, 99 (14%) were classified as out‐of‐scope and included in this analysis. Seventy‐two respondents contributed to these submissions, most of whom were caregivers (n = 58, 81%). Themes mapped across the WHO building blocks, including treatment access, research innovation and translation, health financing, service delivery and environment of care, leadership and governance, health information and communication, and health workforce. Additional concerns were classified as dimensions of care. Conclusions: Out‐of‐scope PSP submissions provide valuable insights into patient, caregiver, and clinician concerns that complement research priorities. They highlight persistent challenges in access to care, supportive services, workforce capacity, information provision, and financial burden, underscoring that many family concerns stem from gaps in implementation, service delivery, and policy, rather than evidence alone. These system‐level challenges must be communicated to funders, policymakers, charities, and consumers to translate these insights into meaningful improvements in care.
- 27 September 2026
- Published by Wiley in Health Expectations
- Vol. 29 (5) , e70884
Open AccessBeyond Research Priorities: Stakeholder‐Identified Health System Challenges From an Australian Childhood Cancer Priority‐Setting Partnership
Background: Priority‐setting partnerships (PSPs) are used to identify research questions that matter most to patients, caregivers, and clinicians. However, submissions that fall outside the scope of research prioritisation are rarely examined despite their potential to reveal important unmet needs. This study explored concerns relevant to practice and policy using the out‐of‐scope questions submitted during the Australian Child and Adolescent Cancer PSP. Methods: We conducted the Australian Child and Adolescent Cancer PSP with the James Lind Alliance to identify research priorities for childhood cancer. An online national survey collected submissions from children and adolescents diagnosed with cancer, their caregivers, and healthcare professionals. We identified submissions that fell outside the PSP scope. These were collated and analysed using qualitative content analysis, followed by framework analysis to deductively map themes to the World Health Organisation Health System Building Blocks, enabling system‐level interpretation of community‐identified concerns. Results: Of the 701 submissions, 99 (14%) were classified as out‐of‐scope and included in this analysis. Seventy‐two respondents contributed to these submissions, most of whom were caregivers (n = 58, 81%). Themes mapped across the WHO building blocks, including treatment access, research innovation and translation, health financing, service delivery and environment of care, leadership and governance, health information and communication, and health workforce. Additional concerns were classified as dimensions of care. Conclusions: Out‐of‐scope PSP submissions provide valuable insights into patient, caregiver, and clinician concerns that complement research priorities. They highlight persistent challenges in access to care, supportive services, workforce capacity, information provision, and financial burden, underscoring that many family concerns stem from gaps in implementation, service delivery, and policy, rather than evidence alone. These system‐level challenges must be communicated to funders, policymakers, charities, and consumers to translate these insights into meaningful improvements in care.
- Open Access
Left ventricular hypertrophy, brain atrophy and cognitive decline in type 2 diabetes mellitus: Diabetes & Dementia (D2) cohort study
BACKGROUND: People with type 2 diabetes mellitus (T2DM) are at higher risk of cerebral small vessel disease and left ventricular hypertrophy (LVH), potentially contributing to cognitive decline and dementia. We aimed to describe brain volume and cognitive trajectories over 2 years in a cohort of people with T2DM and to determine whether LVH causes increased brain atrophy and cognitive decline. METHODS: Diabetes and Dementia (D2) study is a multicentre observational cohort study in Melbourne, Australia. Participants aged >50 years were recruited via 2 hospital outpatient clinics, 3 private clinics, and study advertisements. Participants with pre-existing cognitive impairment, life-limiting medical illness, and severe chronic renal impairment were excluded. Participants attended study visits for brain MRI, transthoracic echocardiography (TTE), and cognitive testing at baseline and 2 years. The exposure was LVH determined on baseline TTE. Pre-specified outcomes were total brain volume (TBV) change and cognitive decline (z-score change≤-1 in any cognitive domain) over 2 years. Regression analyses examined associations between baseline variables and outcomes. A causal inference approach was utilized using inverse probability of treatment weighting to standardize for confounding covariates, excluding participants for non-positivity on age and baseline TBV. RESULTS: Participants were recruited 20May2016 to 20March2020: 2378 screened, 702 eligible, 196 consented, 150 baseline and 123 2-year assessments with complete MRI, TTE, and cognitive data (17.4% attrition). At baseline, LVH was associated with female sex, older age, lower educational attainment, lower mood, hypertension, obesity, beta-blocker use, and smaller TBV. Participants with baseline cognitive impairment exhibited greater brain atrophy. Lower educational attainment, hypertension, and lower baseline cognitive scores were associated with cognitive decline. Causal inference analysis included 62 participants with no LVH (20(32%) women; mean [SD]=66.9[5.9] years), and 31 with LVH (17(55%) women, 67.4[5.4] years). LVH caused lower TBV change: standardized mean difference (95% CI) 6.3 (0.1, 12.5) cm 3 , P = .048. LVH had no effect on cognitive decline. CONCLUSIONS: Brain atrophy and cognitive decline were associated with baseline cognitive impairment. LVH caused less brain atrophy and cognitive decline in people with T2DM. We conclude that guideline-directed LVH therapies such as beta-blockers have both cardioprotective (remodelling) and neuroprotective effects. TRIAL REGISTRATION: ACTRN12616000546459 UTN: U1111-1181-6659 Clinical perspective: What is new?: Causal inference modelling was used to ask whether left ventricular hypertrophy (LVH) caused increased brain atrophy and cognitive decline over 2 years LVH reversed in 40% of participants Increased brain atrophy was associated with baseline cognitive impairment Lower educational attainment, baseline cognitive scores and hypertension were associated with cognitive decline LVH caused less brain atrophy with no effect on cognitive decline What are the clinical implications?: LVH therapies, especially â-blockers, may have both cardioprotective (remodelling) and neuroprotective effects Cognitive impairment in people with T2DM should prompt aggressive risk factor management to prevent brain atrophy and cognitive decline
Open AccessLeft ventricular hypertrophy, brain atrophy and cognitive decline in type 2 diabetes mellitus: Diabetes & Dementia (D2) cohort study
BACKGROUND: People with type 2 diabetes mellitus (T2DM) are at higher risk of cerebral small vessel disease and left ventricular hypertrophy (LVH), potentially contributing to cognitive decline and dementia. We aimed to describe brain volume and cognitive trajectories over 2 years in a cohort of people with T2DM and to determine whether LVH causes increased brain atrophy and cognitive decline. METHODS: Diabetes and Dementia (D2) study is a multicentre observational cohort study in Melbourne, Australia. Participants aged >50 years were recruited via 2 hospital outpatient clinics, 3 private clinics, and study advertisements. Participants with pre-existing cognitive impairment, life-limiting medical illness, and severe chronic renal impairment were excluded. Participants attended study visits for brain MRI, transthoracic echocardiography (TTE), and cognitive testing at baseline and 2 years. The exposure was LVH determined on baseline TTE. Pre-specified outcomes were total brain volume (TBV) change and cognitive decline (z-score change≤-1 in any cognitive domain) over 2 years. Regression analyses examined associations between baseline variables and outcomes. A causal inference approach was utilized using inverse probability of treatment weighting to standardize for confounding covariates, excluding participants for non-positivity on age and baseline TBV. RESULTS: Participants were recruited 20May2016 to 20March2020: 2378 screened, 702 eligible, 196 consented, 150 baseline and 123 2-year assessments with complete MRI, TTE, and cognitive data (17.4% attrition). At baseline, LVH was associated with female sex, older age, lower educational attainment, lower mood, hypertension, obesity, beta-blocker use, and smaller TBV. Participants with baseline cognitive impairment exhibited greater brain atrophy. Lower educational attainment, hypertension, and lower baseline cognitive scores were associated with cognitive decline. Causal inference analysis included 62 participants with no LVH (20(32%) women; mean [SD]=66.9[5.9] years), and 31 with LVH (17(55%) women, 67.4[5.4] years). LVH caused lower TBV change: standardized mean difference (95% CI) 6.3 (0.1, 12.5) cm 3 , P = .048. LVH had no effect on cognitive decline. CONCLUSIONS: Brain atrophy and cognitive decline were associated with baseline cognitive impairment. LVH caused less brain atrophy and cognitive decline in people with T2DM. We conclude that guideline-directed LVH therapies such as beta-blockers have both cardioprotective (remodelling) and neuroprotective effects. TRIAL REGISTRATION: ACTRN12616000546459 UTN: U1111-1181-6659 Clinical perspective: What is new?: Causal inference modelling was used to ask whether left ventricular hypertrophy (LVH) caused increased brain atrophy and cognitive decline over 2 years LVH reversed in 40% of participants Increased brain atrophy was associated with baseline cognitive impairment Lower educational attainment, baseline cognitive scores and hypertension were associated with cognitive decline LVH caused less brain atrophy with no effect on cognitive decline What are the clinical implications?: LVH therapies, especially â-blockers, may have both cardioprotective (remodelling) and neuroprotective effects Cognitive impairment in people with T2DM should prompt aggressive risk factor management to prevent brain atrophy and cognitive decline
- Open Access
- 11 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (1) , 387-396
Real world diagnostic performance of plasma p-tau217 for early-onset Alzheimer's disease in a cognitive disorders tertiary care setting
Background: Plasma p-tau217 shows exceptional diagnostic performance for Alzheimer's disease (AD) in cohort studies. Recent real-world studies support its validity in more diverse populations. Objective: Test the performance of plasma p-tau217 in representative real-world early-onset cognitive disorders patients. Methods: 118 adult patients with cognitive complaints or potential neurodegenerative diseases (ND) from a single healthcare network in Melbourne, Australia, were categorized into three groups based on clinical diagnosis: non-ND (n = 52), early-onset AD (EOAD, n = 39), and non-AD ND (other-ND, n = 27). Plasma p-tau217 was measured using the Simoa ® ALZpath p-Tau 217 Assay. Results: Plasma p-tau217 was elevated in EOAD (mean ± SD: 1.13 ± 0.51) compared with non-ND (0.31 ± 0.27, p = 5.43e-23) and other-ND (0.23 ± 0.10, p = 9.65e-21). ROC analysis revealed excellent diagnostic performance, with AUCs of 0.944 [95% CI:0.893–0.996] for EOAD versus non-ND and 0.984 [0.962–1.000] for EOAD versus other-ND. Using a binary cut-off (p-tau217 > 0.42 pg/mL), 17% non-ND, 95% EOAD and 7% other-ND were A + . Using a two-tiered cut-off approach (0.40 pg/mL > p-tau217 > 0.63 pg/mL), 4% non-ND, 94% EOAD and 0% other-ND were A + . 10% of participants (n = 12) were within the intermediate range. Using the binary cut-off of p-tau217 > 0.64 pg/mL for T+, 100% EOAD and 0% other-ND A + participants, defined by the two-tiered cut-off approach, were T + . No associations of p-tau217 with age, sex, or ethnicity were found within ND groups. P-tau217 was elevated in individuals with severely impaired renal function. Conclusions: The findings support the clinical utility of plasma p-tau217 in the real-world diagnostic evaluation of EOAD. However, careful interpretation of false positive results in patients with severe renal impairment is required.
- 11 September 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 108 (1) , 387-396
Open AccessReal world diagnostic performance of plasma p-tau217 for early-onset Alzheimer's disease in a cognitive disorders tertiary care setting
Background: Plasma p-tau217 shows exceptional diagnostic performance for Alzheimer's disease (AD) in cohort studies. Recent real-world studies support its validity in more diverse populations. Objective: Test the performance of plasma p-tau217 in representative real-world early-onset cognitive disorders patients. Methods: 118 adult patients with cognitive complaints or potential neurodegenerative diseases (ND) from a single healthcare network in Melbourne, Australia, were categorized into three groups based on clinical diagnosis: non-ND (n = 52), early-onset AD (EOAD, n = 39), and non-AD ND (other-ND, n = 27). Plasma p-tau217 was measured using the Simoa ® ALZpath p-Tau 217 Assay. Results: Plasma p-tau217 was elevated in EOAD (mean ± SD: 1.13 ± 0.51) compared with non-ND (0.31 ± 0.27, p = 5.43e-23) and other-ND (0.23 ± 0.10, p = 9.65e-21). ROC analysis revealed excellent diagnostic performance, with AUCs of 0.944 [95% CI:0.893–0.996] for EOAD versus non-ND and 0.984 [0.962–1.000] for EOAD versus other-ND. Using a binary cut-off (p-tau217 > 0.42 pg/mL), 17% non-ND, 95% EOAD and 7% other-ND were A + . Using a two-tiered cut-off approach (0.40 pg/mL > p-tau217 > 0.63 pg/mL), 4% non-ND, 94% EOAD and 0% other-ND were A + . 10% of participants (n = 12) were within the intermediate range. Using the binary cut-off of p-tau217 > 0.64 pg/mL for T+, 100% EOAD and 0% other-ND A + participants, defined by the two-tiered cut-off approach, were T + . No associations of p-tau217 with age, sex, or ethnicity were found within ND groups. P-tau217 was elevated in individuals with severely impaired renal function. Conclusions: The findings support the clinical utility of plasma p-tau217 in the real-world diagnostic evaluation of EOAD. However, careful interpretation of false positive results in patients with severe renal impairment is required.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Impact of type 2 diabetes mellitus on brain volumes and cognitive performance
Background: Type 2 diabetes (T2DM) is recognised as a major contributor to cognitive decline. People with T2DM demonstrate abnormalities on MRI compared to control individuals. The aim of this analysis was to investigate differences in cognitive performance and brain volume between individuals with T2DM participating in the Diabetes‐and‐Dementia (D2) study and a group of healthy controls (HC) part of the Cognition And Neocortical Volume After Stroke (CANVAS) study.Method: One hundred and fifty individuals with T2DM and 36 cognitively‐normal participants completed neuropsychological assessments and a 3T‐MRI scan. FreeSurfer was used to estimate total brain volume (TBV), mean cortical thickness and subcortical volumes, including the thalami and caudate nuclei. Averages between left and right volumes were calculated for subcortical structures. WMH volumes were estimated manually using FLAIR MRI. Five cognitive domains, including attention, visuospatial skills, memory, language and executive function were computed using z‐scores. These domains were used to compare cognitive performance between individuals with and without T2DM.Demographic and clinical comparisons were completed in MATLAB using Two‐Sample t‐test (age), Fisher Exact test (education, sex, APOE‐e4), and Wilcoxon Rank Sum test (BMI). A linear regression model was used to compare cognitive performance between the two groups with correction for age, sex and education level (more/less than 12 years), as well as total intracranial volume for comparing brain volumes.Result: Participants with T2DM were significantly younger, with a higher BMI, had reduced cortical thickness, significantly smaller TBV and smaller subcortical volumes including thalamic, brainstem, amygdala, accumbens area and choroid plexus. Individuals with T2DM exhibited a poorer cognitive performance on tests of language, memory, attention, and visuospatial skills compared to the HC group. There were no significant differences between the two groups in terms of sex, education level, APOE‐e4 carriage, WMH, hippocampal volume (see Table 1).Conclusion: T2DM is associated with accelerated structural brain aging, manifesting as cerebral atrophy and poorer cognitive function.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Open AccessImpact of type 2 diabetes mellitus on brain volumes and cognitive performance
Background: Type 2 diabetes (T2DM) is recognised as a major contributor to cognitive decline. People with T2DM demonstrate abnormalities on MRI compared to control individuals. The aim of this analysis was to investigate differences in cognitive performance and brain volume between individuals with T2DM participating in the Diabetes‐and‐Dementia (D2) study and a group of healthy controls (HC) part of the Cognition And Neocortical Volume After Stroke (CANVAS) study.Method: One hundred and fifty individuals with T2DM and 36 cognitively‐normal participants completed neuropsychological assessments and a 3T‐MRI scan. FreeSurfer was used to estimate total brain volume (TBV), mean cortical thickness and subcortical volumes, including the thalami and caudate nuclei. Averages between left and right volumes were calculated for subcortical structures. WMH volumes were estimated manually using FLAIR MRI. Five cognitive domains, including attention, visuospatial skills, memory, language and executive function were computed using z‐scores. These domains were used to compare cognitive performance between individuals with and without T2DM.Demographic and clinical comparisons were completed in MATLAB using Two‐Sample t‐test (age), Fisher Exact test (education, sex, APOE‐e4), and Wilcoxon Rank Sum test (BMI). A linear regression model was used to compare cognitive performance between the two groups with correction for age, sex and education level (more/less than 12 years), as well as total intracranial volume for comparing brain volumes.Result: Participants with T2DM were significantly younger, with a higher BMI, had reduced cortical thickness, significantly smaller TBV and smaller subcortical volumes including thalamic, brainstem, amygdala, accumbens area and choroid plexus. Individuals with T2DM exhibited a poorer cognitive performance on tests of language, memory, attention, and visuospatial skills compared to the HC group. There were no significant differences between the two groups in terms of sex, education level, APOE‐e4 carriage, WMH, hippocampal volume (see Table 1).Conclusion: T2DM is associated with accelerated structural brain aging, manifesting as cerebral atrophy and poorer cognitive function.
- 25 August 2023
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 23 (3) , 278-286
Vulnerability to environmental and climatic health provocations among women and men hospitalized with chronic heart disease: insights from the RESILIENCE TRIAL cohort
Aims: We aimed to recruit a representative cohort of women and men with multi-morbid chronic heart disease as part of a trial testing an innovative, nurse-co-ordinated, multi-faceted intervention to lower rehospitalization and death by addressing areas of vulnerability to external challenges to their health. Methods and results: The prospective, randomized open, blinded end-point RESILIENCE Trial recruited 203 hospital inpatients (mean age 75.7 ± 10.2 years) of whom 51% were women and 94% had combined coronary artery disease, heart failure, and/or atrial fibrillation. Levels of concurrent multi-morbidity were high (mean Charlson Index of Comorbidity Score 6.5 ± 2.7), and 8.9% had at least mild frailty according to the Rockwood Clinical Frailty Scale. Including the index admission, 19–20% of women and men had a pre-existing pattern of seasonally linked hospitalization (seasonality). Detailed phenotyping revealed that 48% of women and 40% of men had ≥3 physiological factors, and 15% of women and 16% of men had ≥3 behavioural factors likely to increase their vulnerability to external provocations to their health. Overall, 61–62% of women and men had ≥4 combined factors indicative of such vulnerability. Additional factors such as reliance on the public health system (63 vs. 49%), lower education (30 vs. 14%), and living alone (48 vs. 29%) were more prevalent in women. Conclusion: We successfully recruited women and men with multi-morbid chronic heart disease and bio-behavioural indicators of vulnerability to external provocations to their health. Once completed, the RESILIENCE TRIAL will provide important insights on the impact of addressing such vulnerability (promoting resilience) on subsequent health outcomes. Registration: ClinicalTrials.org: NCT04614428.
- 25 August 2023
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 23 (3) , 278-286
Vulnerability to environmental and climatic health provocations among women and men hospitalized with chronic heart disease: insights from the RESILIENCE TRIAL cohort
Aims: We aimed to recruit a representative cohort of women and men with multi-morbid chronic heart disease as part of a trial testing an innovative, nurse-co-ordinated, multi-faceted intervention to lower rehospitalization and death by addressing areas of vulnerability to external challenges to their health. Methods and results: The prospective, randomized open, blinded end-point RESILIENCE Trial recruited 203 hospital inpatients (mean age 75.7 ± 10.2 years) of whom 51% were women and 94% had combined coronary artery disease, heart failure, and/or atrial fibrillation. Levels of concurrent multi-morbidity were high (mean Charlson Index of Comorbidity Score 6.5 ± 2.7), and 8.9% had at least mild frailty according to the Rockwood Clinical Frailty Scale. Including the index admission, 19–20% of women and men had a pre-existing pattern of seasonally linked hospitalization (seasonality). Detailed phenotyping revealed that 48% of women and 40% of men had ≥3 physiological factors, and 15% of women and 16% of men had ≥3 behavioural factors likely to increase their vulnerability to external provocations to their health. Overall, 61–62% of women and men had ≥4 combined factors indicative of such vulnerability. Additional factors such as reliance on the public health system (63 vs. 49%), lower education (30 vs. 14%), and living alone (48 vs. 29%) were more prevalent in women. Conclusion: We successfully recruited women and men with multi-morbid chronic heart disease and bio-behavioural indicators of vulnerability to external provocations to their health. Once completed, the RESILIENCE TRIAL will provide important insights on the impact of addressing such vulnerability (promoting resilience) on subsequent health outcomes. Registration: ClinicalTrials.org: NCT04614428.
- 13 December 2022
- Published by Wiley in Analysis & Sensing
- Vol. 3 (1)
Near‐Infrared Spectroscopic Characterization of Cardiac and Renal Fibrosis in Fixed and Fresh Rat Tissue
Invited for this month‘s cover are the collaborating group(s) of Center for Biospectroscopy at Monash University and Austin Health at the University of Melbourne, University of Eastern Finland and the University of Queensland. The cover‐art shows a handheld near‐infrared spectroscopic probe to detect fibrosis in real time using a murine model. More information can be found in the Research Article by John A. Adegoke, Jaishankar Raman, Bayden R. Wood, and co‐workers.
- 13 December 2022
- Published by Wiley in Analysis & Sensing
- Vol. 3 (1)
Near‐Infrared Spectroscopic Characterization of Cardiac and Renal Fibrosis in Fixed and Fresh Rat Tissue
Invited for this month‘s cover are the collaborating group(s) of Center for Biospectroscopy at Monash University and Austin Health at the University of Melbourne, University of Eastern Finland and the University of Queensland. The cover‐art shows a handheld near‐infrared spectroscopic probe to detect fibrosis in real time using a murine model. More information can be found in the Research Article by John A. Adegoke, Jaishankar Raman, Bayden R. Wood, and co‐workers.
- 12 December 2022
- Published by Wiley in Analysis & Sensing
- Vol. 3 (1)
Front Cover: Near‐Infrared Spectroscopic Characterization of Cardiac and Renal Fibrosis in Fixed and Fresh Rat Tissue (Anal. Sens. 1/2023)
- 12 December 2022
- Published by Wiley in Analysis & Sensing
- Vol. 3 (1)
Front Cover: Near‐Infrared Spectroscopic Characterization of Cardiac and Renal Fibrosis in Fixed and Fresh Rat Tissue (Anal. Sens. 1/2023)
- Open Access
- 13 September 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (9) , 1495
Plasma Angiotensin Converting Enzyme 2 (ACE2) Activity in Healthy Controls and Patients with Cardiovascular Risk Factors and/or Disease
Angiotensin converting enzyme 2 (ACE2) is an endogenous negative regulator of the renin-angiotensin system, a key factor in the development of cardiovascular disease (CVD). ACE2 is also used by SARS-CoV-2 for host cell entry. Given that COVID-19 is associated with hypercoagulability, it is timely to explore the potential relationship between plasma ACE2 activity and the coagulation profile. In this cross-sectional study, ACE2 activity and global coagulation assays (GCA) including thromboelastography, thrombin, and fibrin generation were measured in adult healthy controls (n = 123; mean age 41 ± 17 years; 35% male) and in patients with cardiovascular risk factors and/or disease (n = 258; mean age 65 ± 14 years; 55% male). ACE2 activity was significantly lower in controls compared to patients with cardiovascular risk factors and/or disease (median 0.10 (0.02, 3.33) vs. 5.99 (1.95, 10.37) pmol/mL/min, p < 0.001). Of the healthy controls, 48% had undetectable ACE2 activity. Controls with detectable ACE2 had lower maximum amplitude (p < 0.001). In patients with cardiovascular risk factors and/or disease, those in the 3rd tertile were older and male (p = 0.002), with a higher Framingham grade and increased number of cardiovascular risk factors (p < 0.001). In conclusion, plasma ACE2 activity is undetectable to very low in young healthy controls with minimal clinically relevant associations to GCA. Patients with cardiovascular risk factors and/or disease have increased plasma ACE2 activity, suggesting that it may be an important biomarker of endothelial dysfunction and atherosclerosis.
- 13 September 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (9) , 1495
Open AccessPlasma Angiotensin Converting Enzyme 2 (ACE2) Activity in Healthy Controls and Patients with Cardiovascular Risk Factors and/or Disease
Angiotensin converting enzyme 2 (ACE2) is an endogenous negative regulator of the renin-angiotensin system, a key factor in the development of cardiovascular disease (CVD). ACE2 is also used by SARS-CoV-2 for host cell entry. Given that COVID-19 is associated with hypercoagulability, it is timely to explore the potential relationship between plasma ACE2 activity and the coagulation profile. In this cross-sectional study, ACE2 activity and global coagulation assays (GCA) including thromboelastography, thrombin, and fibrin generation were measured in adult healthy controls (n = 123; mean age 41 ± 17 years; 35% male) and in patients with cardiovascular risk factors and/or disease (n = 258; mean age 65 ± 14 years; 55% male). ACE2 activity was significantly lower in controls compared to patients with cardiovascular risk factors and/or disease (median 0.10 (0.02, 3.33) vs. 5.99 (1.95, 10.37) pmol/mL/min, p < 0.001). Of the healthy controls, 48% had undetectable ACE2 activity. Controls with detectable ACE2 had lower maximum amplitude (p < 0.001). In patients with cardiovascular risk factors and/or disease, those in the 3rd tertile were older and male (p = 0.002), with a higher Framingham grade and increased number of cardiovascular risk factors (p < 0.001). In conclusion, plasma ACE2 activity is undetectable to very low in young healthy controls with minimal clinically relevant associations to GCA. Patients with cardiovascular risk factors and/or disease have increased plasma ACE2 activity, suggesting that it may be an important biomarker of endothelial dysfunction and atherosclerosis.
- 11 August 2022
- Published by Wiley in Analysis & Sensing
- Vol. 3 (1)
Near‐Infrared Spectroscopic Characterization of Cardiac and Renal Fibrosis in Fixed and Fresh Rat Tissue
Clinical diagnosis of fibrosis is currently reliant on conventional methods. The current “gold standard” for fibrosis diagnosis is histological examination of a biopsy, which is labour intensive and requires extensive sample preparation. Here we show that a portable handheld near‐infrared spectrometer coupled with machine learning algorithms can discriminate between kidney and cardiac fibrosis in a rat model of kidney failure compared to healthy rats without kidney failure. The most significant changes in the spectra of fibrotic tissue included shifts in absorption bands at 1509, 1581, 1689 and 1725 nm attributed to collagen components. The best discrimination of fibrosis was achieved in kidney tissue (AUC=0.962), which showed a higher level of fibrosis compared to cardiac tissue (AUC=0.882). The results show the potential of the NIR spectroscopy to detect and to quantify fibrosis in the heart and kidney that in the future could be applied as an intraoperative surgical tool to guide surgical procedures.
- 11 August 2022
- Published by Wiley in Analysis & Sensing
- Vol. 3 (1)
Near‐Infrared Spectroscopic Characterization of Cardiac and Renal Fibrosis in Fixed and Fresh Rat Tissue
Clinical diagnosis of fibrosis is currently reliant on conventional methods. The current “gold standard” for fibrosis diagnosis is histological examination of a biopsy, which is labour intensive and requires extensive sample preparation. Here we show that a portable handheld near‐infrared spectrometer coupled with machine learning algorithms can discriminate between kidney and cardiac fibrosis in a rat model of kidney failure compared to healthy rats without kidney failure. The most significant changes in the spectra of fibrotic tissue included shifts in absorption bands at 1509, 1581, 1689 and 1725 nm attributed to collagen components. The best discrimination of fibrosis was achieved in kidney tissue (AUC=0.962), which showed a higher level of fibrosis compared to cardiac tissue (AUC=0.882). The results show the potential of the NIR spectroscopy to detect and to quantify fibrosis in the heart and kidney that in the future could be applied as an intraoperative surgical tool to guide surgical procedures.